# Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

> **NCT05334693** · PHASE1,PHASE2 · RECRUITING · sponsor: **Belarusian Research Center for Pediatric Oncology, Hematology and Immunology** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** Expanded haploidentical NK cells

## Key facts

- **NCT ID:** NCT05334693
- **Lead sponsor:** Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-01
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05334693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05334693, "Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05334693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*